NTRA - Natera - Stock Price & Dividends

Natera Inc., a pioneering diagnostics company, specializes in developing and commercializing cutting-edge molecular testing services globally. Their innovative product portfolio includes Panorama, a non-invasive prenatal test that detects chromosomal abnormalities in fetuses, including those in twin pregnancies, providing expectant parents with vital information about their baby's health.

The company's Horizon carrier screening test empowers individuals and couples to determine if they are carriers of genetic variations that can cause specific genetic conditions, enabling them to make informed reproductive decisions. Additionally, Vistara, a single-gene NIPT, screens for 25 severe single-gene disorders that can cause skeletal, cardiac, and neurological conditions.

Natera's Spectrum offers preimplantation genetic tests for couples undergoing in vitro fertilization (IVF), while Anora analyzes miscarriage tissue to identify potential genetic causes. Empower, a hereditary cancer screening test, helps identify individuals at risk of developing certain cancers. The company's non-invasive prenatal paternity product allows couples to establish paternity without waiting for the child to be born.

In the field of oncology, Natera's Signatera is a ctDNA blood test that assesses molecular residual disease and monitors disease recurrence in patients previously diagnosed with cancer. Altera is a comprehensive genomic profiling test that analyzes tissue samples, and Prospera evaluates active rejection in patients who have undergone kidney, heart, and lung transplantation. Renasight, a kidney gene panel test, helps diagnose and manage kidney disease.

The company's Constellation is a cloud-based software product that enables laboratory customers to access Natera's algorithms and bioinformatics, facilitating the validation and launch of tests. Natera's products are distributed through a direct sales force and a network of laboratory and distribution partners.

Natera has formed strategic partnerships with BGI Genomics Co., Ltd. to develop and commercialize next-generation sequencing (NGS)-based genetic testing assays, and with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera is headquartered in Austin, Texas, and is committed to advancing genetic testing and improving patient outcomes.